

## NCTN Gynecologic Cancer Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



## **Cross-disease trials:**



## NCTN Gynecologic Cancer Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for
AGCT1531	Ш	Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
		A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate
AGCT1532	Ш	and Poor-Risk Germ Cell Tumors
		A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent
EAY191-N4	П	RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial
		Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II
NRG-GY024	II	Treatment Trial
		A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients
NRG-GY025	П	with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma
		A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-
		oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive,
NRG-GY026	11/111	Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
		A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in
NRG-GY031	I	Recurrent Ovarian and Endometrial Cancer
		A Phase II Study of Tailored Adjuvant Therapy in Pole-Mutated and p53-Wildtype/NSMP Early-Stage
NRG-GY032	П	Endometrial Cancer (RAINBO BLUE & TAPER)
		A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with
		BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First
NRG-GY036	Ш	Line Platinum-Based Chemotherapy
		A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and
		Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally
NRG-GY037	Ш	Advanced Cervical Cancer
		Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in
S2012	11/111	Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
		A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors:
EAY191-E5	II	A ComboMATCH Treatment Trial
		A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6
EAY191-N5	lu .	Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial